The technology features two peptide mimics, P1C21 and P3C21, derived from a phage display library using a human scFv antibody that targets CSPG4, a tumor-associated antigen. These peptides have been rigorously characterized using molecular modeling, kinetic analysis, and systematic amino acid substitution to fine-tune their structural interaction with the antibody. Their ability to block antibody binding to CSPG4-positive melanoma cells confirms their precise mimicry of the antigenic determinant. In vivo studies in mice demonstrated that P1C21 triggers both humoral and cellular immune responses, which are further amplified following exposure to CSPG4-positive melanoma cells.